Shed Light on Oral Semaglutide for Cardiovascular Protection

Oral semaglutide (Rybelsus) is now approved to prevent major adverse CV events in certain high-risk adults with type 2 diabetes.

We know that some injectable GLP-1 agonists (dulaglutide, etc) and oral SGLT2 inhibitors (canagliflozin, etc) reduce major CV events in patients with type 2 diabetes and high CV risk...and are recommended in Canadian guidelines.

Now evidence shows that oral semaglutide 14 mg/day prevents one CV death, nonfatal MI, or nonfatal stroke for every 56 type 2 diabetes patients with CV disease and/or CKD treated for about 4 years...versus placebo.